Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. - Wikidata - awgldk - TriplyDB

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

http://www.wikidata.org/entity/Q34577529

about

Immunomodulation in sepsis: state of the art and future perspective Coagulation cascade in sepsis: getting from bench to bedside?Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study.Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.Anti-inflammatory activity of a novel family of aryl ureas compounds in an endotoxin-induced airway epithelial cell injury model An Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental Data Preventing and treating secondary bacterial infections with antiviral agents Pathogenesis of sepsis: new concepts and implications for future treatment.Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection.Blood hemoperfusion with resin adsorption combined continuous veno-venous hemofiltration for patients with multiple organ dysfunction syndrome.TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen Oxidized low-density lipoprotein, OXPAPC, corrects defects in maturation and cytokine secretion of peripheral blood dendritic cells from sepsis patients.NKT cells in sepsis.The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release.Effects of a potent peroxynitrite decomposition catalyst in murine models of endotoxemia and sepsis.Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis Anti-inflammatory strategies for the treatment of sepsis.Alterations of dendritic cells in sepsis: featured role in immunoparalysis.The dynamics of the early inflammatory response in double-hit burn and sepsis animal models Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis.Protection of mice from lethal Escherichia coli infection by chimeric human bactericidal/permeability-increasing protein and immunoglobulin G1 Fc gene delivery Anti-Staphylococcus aureus single-chain variable region fragments provide protection against mastitis in mice.Time profile of oxidative stress and neutrophil activation in ovine acute lung injury and sepsis.New approaches to the study of sepsis The importance of fever as a predictive symptom for the potency of host's monocytes to release pro- and anti-inflammatory mediators Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.Genetic association studies in VLBW infants exemplifying susceptibility to sepsis--recent findings and implications for future research.Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis Changes in dendritic cell function in the immune response to sepsis. Cell- & tissue-based therapy.Drotrecogin alpha (activated): the treatment for severe sepsis?Dried Ginger (Zingiber officinalis) Inhibits Inflammation in a Lipopolysaccharide-Induced Mouse Model.Perturbed mononuclear phagocyte system in severely burned and septic patients.Sepsis: links between pathogen sensing and organ damage Innate immunity in sepsis pathogenesis and its modulation: new immunomodulatory targets revealed.Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.Cytokine profile in elderly patients with sepsis Aged mice are unable to mount an effective myeloid response to sepsis.

P2860

Q22305766-95E9C818-B312-4812-9342-EBFF72DE244A Q24794170-8750873D-67AA-4CAD-8844-DBD4834D6A80 Q24802551-0184BEE6-FB5F-4F53-8ED8-410E016D0533 Q24812750-EFE3DD19-D97D-40C4-9A1E-4097A211F05C Q25257156-EC009C7C-FCFF-4CA7-B925-6963CC317270 Q28485098-D2AD5A38-480B-464D-B515-1878555ADB3D Q30000073-3AFCC8D7-218F-421F-8EB2-775B6A0E498C Q30401260-2DBF0294-93EB-4AD2-8F5C-164E24FF53FE Q33813681-98213C17-8F5F-4223-9700-A411449651EC Q34026905-88649891-7C4B-4F5C-96CA-46AA7E2875D9 Q34032143-40F39641-A881-4B1A-BA2B-CF5ADBCD341D Q34066228-E3A80303-2443-41C9-8AC0-42C33D18B3A3 Q34167066-571C5B2F-1806-4944-9187-D3EF5F441509 Q34189487-4910507C-1DEF-4B18-98DB-9016850C09F3 Q34721762-191725C8-9620-4ABF-B3EE-5FB8FB70DD4D Q34987898-26A0C525-C82C-4DC9-9D62-05A799B9DED3 Q34999537-AA95FF8E-38B3-4EB6-BFC5-929AB482F59A Q35091478-5F649831-ECD4-4713-A746-B049B637B591 Q35093632-A751FA3B-2C13-4B95-9463-B7C0BD7B2904 Q35188317-FA3735DA-B4B0-45E9-8CFD-1708A40F7E09 Q35256994-86593641-EA1B-4715-912A-9D03B462492F Q35567246-A0A78830-8855-4777-B75F-77E10B0D11F8 Q35629894-1B6AEC1F-EE24-497E-B450-65F451A5B78A Q35635915-61CD519D-1013-4631-90EF-0A9D64C1D4E9 Q35825443-2C4FDE35-C0EC-4AD8-B7F1-21B4ECEA9902 Q36283001-CADBBF60-DA79-4771-8A00-FBF3B9DDFD22 Q36492375-8B2F3FA3-FDB1-4004-95E2-F57D9AA8B7ED Q36513681-A0D1DBFF-0D95-4497-86A7-5BB0AB4884D9 Q36744024-44F6616B-3B89-4423-A3E3-796B621EF397 Q36789328-4BE7E91D-4EE8-4DED-8FE3-73AF61F3B480 Q36829883-D64EC7DC-E81E-4987-917F-96B0FD521869 Q36897366-D426253C-4186-4FDC-A3E6-D187E5E9D8DF Q36981698-2D144D48-E6D4-4C07-9624-BC35F065CC2B Q37015500-034CB1E8-5E82-4464-9542-40E19EB7E9C0 Q37074014-1A4B5494-34FF-49A5-87B2-066FCBA4E731 Q37239817-5348041E-7C76-4726-9416-563227ACC810 Q37364297-A94F94CC-BE04-4FA6-A781-15F70306051B Q37367885-4C3D3FFC-13BB-4DA4-8696-02C84F216C4F Q37409738-97A9F236-6E4C-4E8E-AC87-A20EA326F73C Q37448845-CE0F5742-119F-41E4-AE2C-D65BCDC22895

P2860

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

http://www.wikidata.org/entity/Q34577529

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@ast

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@en

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@nl

type

label

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@ast

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@en

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@nl

prefLabel

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@ast

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@en

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@nl

P1433

Q34577529-4D08D3A2-2A0E-4862-AE5A-5937DFCE4A84

P1476

Q34577529-1C8AB593-00DE-416D-89FF-31A815DD9923

P2093

Q34577529-1A65BB07-47A6-4C2F-944B-02796A21ECBC

Q34577529-56488550-B208-4475-9D99-0E9CBDF0312B

P2860

Q34577529-00A7BF9D-1284-4B06-AF1F-25D946DB3274

Q34577529-0928573E-F1E6-478C-9843-069E92CCCB5D

Q34577529-0C69A834-11D2-4DA6-8DAF-7675793F6BEB

Q34577529-1055C8C7-4E19-4B53-B7D2-6AD44CBBF4AA

Q34577529-15E3D19E-FB42-43B5-86AE-242C1091F867

Q34577529-161F4D05-4F62-4CD3-94E8-8C8CE31757CF

Q34577529-1C3AF1A8-C450-4C38-BE05-0A978D2EDA93

Q34577529-1EA5923D-90DF-4116-96C0-A0CB429F93B8

Q34577529-22E373AB-5102-4A2D-99B2-78E9D74023AE

Q34577529-2524D34B-8AF5-467C-8A22-24A480B0A93A

P304

Q34577529-95320217-7C99-453E-992C-CDFF14F3F0B2

P31

Q34577529-92CC4FFE-2A4D-4328-A124-5585C9BDBBC7

P356

Q34577529-859F9A48-5582-4DF6-B362-F62688F05D6F

P407

Q34577529-BDA1C435-EF20-49D5-8C63-7E9AC24B589A

P433

Q34577529-9D6F24B6-FCF0-4D65-BAE1-C1B50E3E935F

P478

Q34577529-446C5C8E-44B2-4670-A0B4-4722A4971A0E

P50

Q34577529-A4A36318-1E15-414C-B149-E2B1C62194E1

P577

Q34577529-9D0BB082-B423-4494-9B4F-1F9C5039C8E0

P5875

Q34577529-17B5040C-759A-453B-A242-9172127679B2

P698

Q34577529-C7CB0975-8C6D-4EF3-BCF3-C84BE2D37402

P921

Q34577529-8935A600-973D-4CA9-A7AC-F5CE3C7437C8

P356

P1433

Clinical Infectious Diseases

P1476

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

@en

P2093

Marc-Jacques Dubois

http://www.w3.org/2001/XMLSchema#string

Qinghua Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients

HMG-1 as a late mediator of endotoxin lethality in mice

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients

Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations

Efficacy and safety of recombinant human activated protein C for severe sepsis

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

Filgrastim in patients with pneumonia and severe sepsis or septic shock.

P304

1084-1093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/339549

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Louis Vincent

P577

2002-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11449535

http://www.w3.org/2001/XMLSchema#string

P698

11914997

http://www.w3.org/2001/XMLSchema#string

P921